Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells

Judith Grau Expósito, David Perea, Marina Suppi, Núria Massana, Ander Vergara, María José Soler, Benjamin Trinité, Julià Blanco, Javier García-Pérez, Jose Alcami, Anna Serrano-Mollar, Joel Rosado Rodríguez, Vicenç Falcó, Meritxell Genescà Ferrer, Maria José Buzón

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

18 Cites (Scopus)

Resum

The development of physiological models that reproduce SARS-CoV-2 infection in primary human cells will be instrumental to identify host-pathogen interactions and potential therapeutics. Here, using cell suspensions directly from primary human lung tissues (HLT), we have developed a rapid platform for the identification of viral targets and the expression of viral entry factors, as well as for the screening of viral entry inhibitors and anti-inflammatory compounds. The direct use of HLT cells, without long-term cell culture and in vitro differentiation approaches, preserves main immune and structural cell populations, including the most susceptible cell targets for SARS-CoV-2; alveolar type II (AT-II) cells, while maintaining the expression of proteins involved in viral infection, such as ACE2, TMPRSS2, CD147 and AXL. Further, antiviral testing of 39 drug candidates reveals a highly reproducible method, suitable for different SARS-CoV-2 variants, and provides the identification of new compounds missed by conventional systems, such as VeroE6. Using this method, we also show that interferons do not modulate ACE2 expression, and that stimulation of local inflammatory responses can be modulated by different compounds with antiviral activity. Overall, we present a relevant and rapid method for the study of SARS-CoV-2. The early stages of laboratory identification of therapeutics against pathogens is usually based on the use of immortalized cell lines, as exemplified by many studies screening antivirals against SARS-CoV-2. Cell lines are manipulated for their continuous growth which offers several advantages, however they do not fully reproduce the behavior of primary cells nor the complexity of heterogeneous populations. In this study, we overcome this limitation by using surgical resections to establish human lung tissue (HLT) cell cultures ready for drug evaluation. First, we show that HLT preserves lung cell composition, including the main SARS-CoV-2 cellular target, namely alveolar type-2 cells, as well as the proteins required for viral entry into the cells: ACE2, CD147, TMPRSS2 and AXL. Moreover, using HLT cells we identified new antiviral drug candidates missed by conventional systems, and anti-inflammatory compounds that module molecules associated with SARS-CoV-2 infection. In summary, we have established a physiological model that can be used for the identification of novel anti-SARS-CoV-2 therapeutics and other respiratory pathogens
Idioma originalAnglès
RevistaPLoS Pathogens
Volum18
DOIs
Estat de la publicacióPublicada - 2022

Fingerprint

Navegar pels temes de recerca de 'Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells'. Junts formen un fingerprint únic.

Com citar-ho